WebDoctor Encyclopedia

Article

Autologous Stem Cell Transplant

What is an autologous stem cell transplant?

An autologous stem cell transplant (often called an auto transplant or ASCT) is a treatment that allows doctors to give very high doses of chemotherapy, sometimes with radiotherapy, and then rescue the bone marrow using the patient’s own stem cells. “Autologous” means “from yourself”.

The bone marrow contains blood stem cells, which make all red cells, white cells and platelets. High-dose chemotherapy can kill cancer cells more effectively than standard doses, but it also destroys the bone marrow. By collecting and freezing your own stem cells beforehand, and giving them back after the chemotherapy, the marrow can recover in a few weeks.

Strictly speaking, the stem cells themselves do not treat the cancer. The high-dose chemotherapy is the treatment, and the stem cells act as a rescue. This is different from an allogeneic transplant, in which stem cells come from a donor and the donor’s immune cells also attack the cancer.

Autologous versus allogeneic transplant

Feature Autologous transplant Allogeneic transplant
Source of stem cells Your own A matched donor
Donor needed No Yes
Graft-versus-host disease Does not occur A major risk
Immune attack on cancer from graft No Yes (graft-versus-tumour effect)
Risk of treatment-related death Lower Higher
Main uses Myeloma, lymphoma, some solid tumours Leukaemias, myelodysplastic syndromes, some lymphomas

A brief history

The first successful bone marrow transplants were carried out in the 1950s and 1960s. Early autologous transplants used marrow collected from the hip bones under anaesthetic. Today, almost all autologous transplants use stem cells collected from the blood, which is simpler for the patient and leads to faster recovery of blood counts. A review of stem cell transplantation describes this shift towards blood-derived stem cells and the growth of transplant as a treatment for many blood cancers (Copelan, 2006).

1. Key facts at a glance

Feature Details
Type of treatment High-dose chemotherapy with stem cell rescue
Main uses Multiple myeloma, relapsed lymphoma, some solid tumours in children and young adults
Stem cell source Usually your own blood, collected after growth factor injections
Common high-dose drugs Melphalan for myeloma; BEAM or similar combinations for lymphoma
Hospital stay Usually 2-4 weeks; some centres offer outpatient care
Recovery Blood counts recover in 2-3 weeks; full recovery takes several months
Main risks Infection, mouth sores, diarrhoea, tiredness, rarely organ damage

2. How it works

Stage Purpose
Induction treatment Standard treatment to shrink the cancer first
Stem cell mobilisation Growth factor injections, sometimes with chemotherapy or plerixafor, push stem cells out of the marrow into the blood
Collection (apheresis) Stem cells are filtered from the blood and frozen
Conditioning High-dose chemotherapy kills remaining cancer cells and wipes out the marrow
Stem cell infusion Thawed stem cells are given back through a drip
Engraftment Stem cells travel to the marrow and start making new blood cells

A review of conditioning describes how the early idea was simple: give the highest tolerable dose to eliminate the disease, then restore blood production with the graft (Gyurkocza and Sandmaier, 2014). For autologous transplants this principle still applies.

3. Who it is for

Conditions treated

Condition Role of autologous transplant
Multiple myeloma Standard part of first-line treatment for fit patients
Hodgkin lymphoma Relapsed disease that still responds to chemotherapy
Diffuse large B-cell lymphoma Relapsed disease; CAR-T is now often preferred for early relapse
Mantle cell lymphoma Consolidation after first treatment in some fit patients
Primary central nervous system lymphoma Consolidation with drugs that reach the brain
Peripheral T-cell lymphoma Consolidation in first remission for some types
AL amyloidosis Selected patients with good organ function
POEMS syndrome Widespread disease in suitable patients
Neuroblastoma High-risk disease in children
Testicular germ cell tumours Relapsed disease, sometimes as tandem transplants

Who may be suitable

Factor Typical consideration
Fitness Good general health and organ function
Age Biological fitness matters more than age; many people over 65 are treated
Disease response The cancer usually needs to respond to prior chemotherapy
Stem cell collection Enough stem cells must be collected
Support Someone to help during recovery at home

Why transplant is used in myeloma

Myeloma is a cancer of plasma cells in the bone marrow that is very sensitive to the drug melphalan. Giving melphalan at a high dose deepens the response achieved by first-line drugs. In the IFM 2009 trial, more people who had a transplant reached a complete response and had no detectable remaining disease on sensitive tests (Attal et al., 2017).

Tandem transplants

In some situations, two autologous transplants are given a few months apart. This is called a tandem transplant. It is used in selected people with high-risk myeloma, in high-risk neuroblastoma in children and in relapsed germ cell tumours. Enough stem cells must be collected at the start for both procedures.

4. Before treatment

Step Details
Work-up Heart scan, lung function, kidney and liver tests, infection screening
Dental check Treat any problems before high-dose chemotherapy
Central line A tunnelled line or PICC is placed
Fertility preservation Sperm or egg storage if appropriate
Mobilisation Daily G-CSF injections for 4-5 days, sometimes after a dose of chemotherapy
Apheresis Usually 1-3 days of collection, 3-5 hours each
Cell freezing Cells are frozen until needed

5. What to expect: step by step

Step Timing What happens
1. Admission Day -2 to -7 Admitted to a transplant unit, often in a single room
2. High-dose chemotherapy Days -7 to -1 One or several days, depending on the regimen
3. Stem cell infusion Day 0 Cells are thawed and given through a drip over minutes to an hour; it feels like a blood transfusion
4. Low-count period Days 3-12 Blood counts fall to very low levels; risk of infection, bleeding and mouth sores
5. Supportive care Throughout Antibiotics, transfusions, pain relief, nutrition support
6. Engraftment Days 10-15 White cells start to rise
7. Discharge Usually days 14-21 Once counts recover and you can eat and drink
8. Early follow-up Weeks 3-12 Frequent clinic visits and blood tests

The day of infusion

Many people call the infusion day their “new birthday”. The stem cells are kept in a preservative that can cause a strong taste of sweetcorn or garlic, a tickly cough or nausea for a few hours. You may notice the smell on your breath for a day or two.

6. Side effects and risks

Side effect When it occurs Notes
Infection Mostly during low counts Fever needs urgent antibiotics
Mouth sores (mucositis) Days 3-14 Can make eating painful; strong pain relief may be needed
Nausea, vomiting and diarrhoea First 2 weeks Anti-sickness medicines and fluids
Hair loss Weeks 2-3 Regrows over a few months
Tiredness Weeks to months The most persistent effect
Bleeding Low platelets Platelet transfusions
Engraftment syndrome Around engraftment Fever, rash, fluid retention; usually settles with steroids
Organ damage Uncommon Heart, lung, liver or kidney
Infertility Often High-dose chemotherapy commonly affects fertility
Second cancers Rare, years later Including blood cancers
Treatment-related death Low, usually 1-2% or less Higher in people with other illnesses

7. Results and outlook

Study Main finding
IFM 2009, newly diagnosed myeloma (700 adults) Transplant after RVD induction lengthened median progression-free survival from 36 to 50 months, though overall survival at four years was similar (Attal et al., 2017)
PARMA, relapsed chemotherapy-sensitive lymphoma (109 randomised) Five-year event-free survival was 46% with transplant versus 12% with standard chemotherapy, and overall survival 53% versus 32% (Philip et al., 1995)

The PARMA trial established autologous transplant as a standard for relapsed aggressive lymphoma that still responds to chemotherapy. In myeloma, transplant remains a standard option for fit patients, although newer drug combinations continue to change the picture.

8. Recovery and aftercare

Recovery timeline

Period What to expect
Weeks 1-4 after discharge Tiredness, low appetite; frequent clinic visits
Months 1-3 Energy slowly returns; avoid crowds and infections
Months 3-6 Many people return to work or study, often part time
Around 6-12 months Repeat childhood vaccinations begin, as immunity from earlier vaccines is lost
Long term Follow-up for disease control and late effects

Protecting yourself from infection

  • Wash hands often and ask visitors to do the same
  • Avoid people with colds, flu or stomach bugs
  • Follow food safety advice, such as avoiding undercooked meat and unpasteurised products
  • Take preventive medicines such as antivirals as prescribed
  • Call your team for a temperature of 38 C or higher

Maintenance treatment

In myeloma, lenalidomide maintenance is usually started a few months after transplant to keep the disease under control for longer. In the IFM 2009 trial, both groups received a year of lenalidomide maintenance (Attal et al., 2017).

Eating and drinking

Taste changes, mouth soreness and poor appetite are common for weeks. Small, frequent meals and high-calorie drinks can help you regain weight and strength. A dietitian at the transplant centre can give advice tailored to you.

Late effects to watch for

Late effect What can help
Persistent tiredness Gradual exercise programmes
Early menopause or low testosterone Hormone checks and replacement if needed
Thyroid problems Regular blood tests, especially after radiotherapy
Cataracts Eye checks, particularly after total body irradiation or steroids
Bone thinning Bone density scans, calcium and vitamin D
Second cancers Routine screening and reporting new symptoms

Driving, travel and pets

Most people are advised not to drive for the first few weeks, while tiredness and medicines may affect concentration. Avoid long-haul travel and crowded places until your team agrees. Ask someone else to clean litter trays, bird cages and fish tanks for a few months, as these can carry infections.

Emotional recovery

The months after a transplant can bring mixed feelings: relief that the main treatment is over, along with worry about the cancer returning and frustration at slow progress. Support from transplant nurses, psychologists, peer groups and family is valuable. Many centres run survivorship clinics.

Returning to everyday life

Recovery is rarely a straight line. Good days are often followed by tired ones, and it can take six months to a year before energy feels close to normal. Setting small goals, such as a daily walk, and gradually increasing them helps rebuild fitness. Talk to your employer early about a phased return to work, and ask your team for a letter explaining what support you need.

9. Alternatives

Alternative When it is considered
Continued standard-dose drug treatment Myeloma in people who are not fit for, or choose not to have, a transplant
CAR-T cell therapy Early relapse or resistant large B-cell lymphoma, myeloma
Allogeneic stem cell transplant When a donor graft-versus-tumour effect is needed
Bispecific antibodies Relapsed lymphoma and myeloma
Radiotherapy Localised disease
Clinical trials New combinations

10. Frequently asked questions

Question Answer
Is it an operation? No; the stem cells are given through a drip
Will I need a donor? No; your own stem cells are used
Can the cancer be in the collected cells? A small number of cancer cells may be present, but this is rarely the main cause of relapse
How long will I be in hospital? Usually 2-4 weeks
Will I lose my hair? Usually yes, temporarily
When can I go back to work? Often after 3-6 months
Can I have a second transplant? Sometimes, if stem cells were stored and the disease returns after a long remission

11. Questions to ask your care team

  • What are the benefits of a transplant for my condition?
  • Which high-dose regimen will I receive?
  • How long will I be in hospital?
  • How will my fertility be affected?
  • What support will I need at home?
  • When can I return to work and normal life?
  • Will I need maintenance treatment afterwards?

Resources

  1. Attal, M. et al. (2017) ‘Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma’, New England Journal of Medicine, 376(14), pp. 1311-1320.
  2. Copelan, E.A. (2006) ‘Hematopoietic stem-cell transplantation’, New England Journal of Medicine, 354(17), pp. 1813-1826.
  3. Gyurkocza, B. and Sandmaier, B.M. (2014) ‘Conditioning regimens for hematopoietic cell transplantation: one size does not fit all’, Blood, 124(3), pp. 344-353.
  4. Philip, T. et al. (1995) ‘Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma’, New England Journal of Medicine, 333(23), pp. 1540-1545.
  5. National Cancer Institute (2026) Stem Cell and Bone Marrow Transplants for Cancer. Available at: https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant (Accessed: October 2026).

Prepared by the editorial team, October 2026.